Bicyclic Heteroaryl Compounds

Abstract

This invention relates to compounds of the general formula: in which the variable groups are as defined herein, and to their preparation and use.

1 - 22 . (canceled) 
     
     
         23 . A compound of the formula: 
       
         
           
           
               
               
           
         
       
       wherein:
 Ring A is a 5- or 6-membered aryl or heteroaryl ring; 
 Ring B is a 5- or 6-membered aryl or heteroaryl ring; 
 L 1  is selected from NR 1 C(O), C(O)NR 1 , NR 1 C(O)O, NR 1 C(O)NR 1 , and OC(O)NR 1 ; 
 each occurrence of R a  and R b  is independently halo, —CN, —NO 2 , —R 4 , —OR 2 , —NR 2 R 3 , —C(O)YR 2 , —OC(O)YR 2 , —NR 2 C(O)YR 2 , —SC(O)YR 2 , —NR 2 C(═S)YR 2 , —OC(═S)YR 2 , —C(═S)YR 2 , —YC(═NR 3 )YR 2 , —YP(═O)(YR 4 )(YR 4 ), —Si(R 2 ) 3 , —NR 2 SO 2 R 2 , —S(O) r R 2 , —SO 2 NR 2 R 3  or —NR 2 SO 2 NR 2 R 3 , wherein each Y is independently a bond, —O—, —S— or —NR 3 —; 
 R e , at each occurrence, is independently halo, —CN, —NO 2 , —R 4 , —OR 2 , —NR 2 R 3 , —C(O)YR 2 , —OC(O)YR 2 , —NR 2 C(O)YR 2 , —SC(O)YR 2 , —NR 2 C(═S)YR 2 , —OC(═S)YR 2 , —C(═S)YR 2 , —YC(═NR 3 )YR 2 , —YP(═O)(YR 4 )(YR 4 ), —Si(R 2 ) 3 , —NR 2 SO 2 R 2 , —S(O) r R 2 , —SO 2 NR 2 R 3  or —NR 2 SO 2 NR 2 R 3 , wherein each Y is independently a bond, —O—, —S— or —NR 3 —; 
 R 1 , R 2  and R 3  are independently H, alkyl, alkenyl, alkynyl, cycloalkyl, cycloalkenyl, cycloalkynyl, aryl, heterocyclyl, or heteroaryl; 
 or R 2  and R 3 , taken together with the atom to which they are attached, form a 5- or 6-membered saturated, partially saturated or unsaturated ring, which contains 0-2 heteroatoms selected from N, O and S(O) r ; 
 each occurrence of R 4  is independently alkyl, alkenyl, alkynyl, cycloalkyl, cycloalkenyl, cycloalkynyl, aryl, heterocyclyl, or heteroaryl; 
 each of the alkyl, alkenyl, alkynyl, cycloalkyl, cycloalkenyl, cycloalkynyl and heterocyclyl moieties is optionally substituted with one or more groups selected from halo, —CN, —R 4 , —OR 2 , —S(O) r R 2 , —SO 2 NR 2 R 3 , —NR 2 R 3 , —(CO)YR 2 , —O(CO)YR 2 , —NR 2 (CO)YR 2 , —S(CO)YR 2 , —NR 2 C(═S)YR 2 , —OC(═S)YR 2 , —C(═S)YR 2 , —YC(═NR 3 )Y′R 2 , —COCOR 2 ,—COMCOR 2 , —YP(═O)(YR 4 )(YR 4 ), —Si(R 2 ) 3 , —NO 2 , —NR 2 SO 2 R 2 , —NR 2 SO 2 NR 2 R 3 , ═O, ═S, ═NH, ═NNR 2 R 3 , ═NNHC(O)R 2 , ═NNHCO 2 R 2 , and ═NNHSO 2 R 2 , wherein M is a 1-6 carbon alkyl group; 
 each of the aryl and heteroaryl moieties is optionally substituted on an unsaturated carbon atom with one or more groups selected from halo, —CN, —R 4 , —OR 2 , —S(O) r R 2 , —SO 2 NR 2 R 3 , —NR 2 R 3 , —(CO)YR 2 , —O(CO)YR 2 , —NR 2 (CO)YR 2 , —S(CO)YR 2 , —NR 2 C(═S)YR 2 , —OC(═S)YR 2 , —C(═S)YR 2 , —YC(═NR 3 )Y′R 2 , —COCOR 2 ,—COMCOR 2 , —YP(═O)(YR 4 )(YR 4 ), —Si(R 2 ) 3 , —NO 2 , —NR 2 SO 2 R 2 , and —NR 2 SO 2 NR 2 R 3 ; 
 m is 0, 1, 2, 3 or 4; 
 p is 0, 1, 2, 3, 4 or 5; 
 r is 0, 1 or 2; and 
 s is 0, 1, 2, 3 or 4, 
 
       or a pharmaceutically acceptable salt-thereof. 
     
     
         24 . The compound of  claim 23  of the formula: 
       
         
           
           
               
               
           
         
       
       wherein:
 Ring C is a 5- or 6-membered heterocyclyl, or heteroaryl ring, comprising carbon atoms and 1-3 heteroatoms independently selected from O, N and S(O) r ; 
 R c , at each occurrence, is independently selected from halo, ═O, —CN, —NO 2 , —R 4 , —OR 2 , —NR 2 R 3 , —C(O)YR 2 , —OC(O)YR 2 , —NR 2 C(O)YR 2 , —Si(R 2 ) 3 , —SC(O)YR 2 , —NR 2 C(═S)YR 2 , —OC(═S)YR 2 , —C(═S)YR 2 , —YC(═NR 3 )YR 2 , —YP(═O)(YR 4 )(YR 4 ), —NR 2 SO 2 R 2 , —S(O) r R 2 , —SO 2 NR 2 R 3  and —NR 2 SO 2 NR 2 R 3 , wherein each Y is independently a bond, —O—, —S— or —NR 3 —; and,
 v is 0, 1, 2, 3, 4 or 5. 
 
 
     
     
         25 . The compound of  claim 24  wherein Ring A and Ring B are independently a 5- or 6-membered aryl. 
     
     
         26 . The compound of  claim 25  wherein Ring C is imidazolyl. 
     
     
         27 . The compound of  claim 23  having the formula: 
       
         
           
           
               
               
           
         
       
       wherein:
 Ring D represents a 5- or 6-membered heterocyclyl or heteroaryl ring comprising carbon atoms and 1-3 heteroatoms independently selected from O, N and S(O) r ; 
 L 2  is (CH 2 ) z , O(CH 2 ) x , NR 3 (CH 2 ) x , S(CH 2 ) x  and (CH 2 ) x NR 3 C(O)(CH 2 ) x  in either direction; 
 R d , at each occurrence, is H, halo, ═O, —CN, —NO 2 , —R 4 , —OR 2 , —NR 2 R 3 , —C(O)YR 2 , —OC(O)YR 2 , —NR 2 C(O)YR 2 , —SC(O)YR 2 , —NR 2 C(═S)YR 2 , —OC(═S)YR 2 , —C(═S)YR 2 , —YC(═NR 3 )YR 2 , —YP(═O)(YR 4 )(YR 4 ), —Si(R 2 ) 3 , —NR 2 SO 2 R 2 , —S(O) r R 2 , —SO 2 NR 2 R 3  or —NR 2 SO 2 NR 2 R 3 , wherein each Y is independently a bond, —O—, —S— or —NR 3 —; 
 R 2  and R 3  are independently H, alkyl, alkenyl, alkynyl, cycloalkyl, cycloalkenyl, cycloalkynyl, aryl, heterocyclyl, or heteroaryl; 
 or R 2  and R 3 , taken together with the atom to which they are attached, form a 5- or 6-membered saturated, partially saturated or unsaturated ring, which contains 0-2 heteroatoms selected from N, O and S(O) r ; 
 each occurrence of R 4  is independently alkyl, alkenyl, alkynyl, cycloalkyl, cycloalkenyl, cycloalkynyl, aryl, heterocyclyl, or heteroaryl; 
 each of the alkyl, alkenyl, alkynyl, cycloalkyl, cycloalkenyl, cycloalkynyl, and heterocyclyl moieties is optionally substituted with one or more groups selected from halo, —CN, —R 4 , —OR 2 , —S(O) r R 2 , —SO 2 NR 2 R 3 , —NR 2 R 3 , —(CO)YR 2 , —O(CO)YR 2 , —NR 2 (CO)YR 2 , —S(CO)YR 2 , —NR 2 C(═S)YR 2 , —OC(═S)YR 2 , —C(═S)YR 2 , —YC(═NR 3 )Y′R 2 , —COCOR 2 ,—COMCOR 2 , —YP(═O)(YR 4 )(YR 4 ), —Si(R 2 ) 3 , —NO 2 , —NR 2 SO 2 R 2 , —NR 2 SO 2 NR 2 R 3 , ═O, ═S, ═NH, ═NNR 2 R 3 , ═NNHC(O)R 2 , ═NNHCO 2 R 2 , and ═NNHSO 2 R 2 , wherein M is a 1-6 carbon alkyl group; 
 each of the aryl and heteroaryl moieties is optionally substituted on an unsaturated carbon atom with one or more groups selected from halo, —CN, —R 4 , —OR 2 , —S(O) r R 2 , —SO 2 NR 2 R 3 , —NR 2 R 3 , —(CO)YR 2 , —O(CO)YR 2 , —NR 2 (CO)YR 2 , —S(CO)YR 2 , —NR 2 C(═S)YR 2 , —OC(═S)YR 2 , —C(═S)YR 2 , —YC(═NR 3 )Y′R 2 , —COCOR 2 ,—COMCOR 2 , —YP(═O)(YR 4 )(YR 4 ), —Si(R 2 ) 3 , —NO 2 , —NR 2 SO 2 R 2 , and —NR 2 SO 2 NR 2 R 3 ; 
 w is 0, 1, 2, 3, 4 or 5; 
 x is 0, 1, 2 or 3; and, 
 z is 1, 2, 3 or 4. 
 
     
     
         28 . The compound of  claim 27 , wherein Ring A and Ring B are independently a 5- or 6-membered aryl. 
     
     
         29 . The compound of  claim 28 , wherein Ring D is piperizinyl and L 2  is CH 2 . 
     
     
         30 . The compound of  claim 29  wherein s is 0, m is 1, p is 1, R a  is methyl, R b  is CF 3 , and R d  is —CH 3  or —CH 2 CH 2 OH. 
     
     
         31 . A composition comprising a compound of  claim 23  or a pharmaceutically acceptable salt thereof and a pharmaceutically acceptable carrier, diluent or vehicle.